Kinases from HIV-1 Infected Exosomes Drive Cell Cycle Progression in Recipient Cells

Authors

  • Isabel Wang Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA
  • Anastasia Williams Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA
  • Fatah Kashanchi Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA

Abstract

Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that depletes CD4+ cells and progresses into acquired immunodeficiency syndrome (AIDS) if left untreated [1]. As of 2022, HIV-1 caused around 88.4 million infections and 42.3 million deaths [2]. Currently, combination antiretroviral therapy (cART) is an effective therapeutic, which prevents AIDS by blocking various stages of the HIV-1 life cycle; however, it is not a cure, as low levels of viral production persist in cART patients [3]. This is partially due to exosomes, which are membrane-bound vesicles that transport proteins and nucleic acids between cells for communication [4]. When infected, exosomes carry viral and host materials that instigate infection, such as exosome-associated host kinases CDK10, GSK-3B, and MAPK8 [4, 5]. In this study, we examined how the kinases influence cell cycle progression, a key aspect of HIV-1 pathogenesis. Exosomes were isolated from infectious ACH2 and U1 cells, treated with kinase-suppressing drugs, and administered to U937 and CEM cells in G0. Levels of cell cycle proteins were then assessed through western blot to determine cycle status. Cyclins D and E, which engage in G1/S transition, decreased in CEM cells treated with ACH2 exosomes on CDK10-inhibiting NVP2, suggesting inhibition causes G1 arrest. Conversely, Cyclin E and CDK2 increased in U937 cells treated with U1 exosomes on GSK-3B-inhibiting AZD2858 and MAPK8-inhibiting DB07268, indicating inhibition allows for G1/S progression. These findings enhance our understanding of host protein impact in HIV-1 proliferation and can be considered in the development of novel therapies.

 

  1. Dornadula, G. (1999). Residual hiv-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA, 282(17), 1627. https://doi.org/10.1001/jama.282.17.1627
  2. HIV. (n.d.). World Health Organization. https://www.who.int/data/gho/data/themes/hiv-aids#:~:text=Globally%2C%2039.0%20million%20%5B33.1%E2%80%93,considerably%20between%20countries%20and%20regions
  3. HIV and AIDS: The Basics. (n.d.). HIVinfo.NIH.gov. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-aids-basics#:~:text=The%20human%20immunodeficiency%20virus%20(HIV,advanced%20stage%20of%20HIV%20infection.
  4. Madison, M., & Okeoma, C. (2015). Exosomes: Implications in HIV-1 pathogenesis. Viruses, 7(7), 4093-4118. https://doi.org/10.3390/v7072810
  5. Mensah, G. et al. (2024). Effect of Kinases in Extracellular Vesicles from HIV-1-Infected Cells on Bystander Cells. Cells, 13, x. https://doi.org/10.3390/xxxxx. In preparation. 

Published

2024-10-13

Issue

Section

College of Science: School of Systems Biology